Home › Research › Treatments
Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil
Price Udo Price, Robert Heggie, Júlio César Moriguti, Leonardo Régis Leira Pereira. Value in Health Regional Issues, 2025-05-27
Topic: Amyloid, tau and blood-test diagnosis
In the base-case analysis from the healthcare perspective, SoC was more clinically effective than BSC with a cost per QALY of $5211. For lecanemab versus SoC, the cost per QALY gained was $2 098 225, whereas donanemab versus lecanemab was $1 460 400. The SoC is a cost-effective pharmacological intervention for AD, offering the lowest cost per QALY gains over a 20-year period.
Key findings
- In the base-case analysis from the healthcare perspective, SoC was more clinically effective than BSC with a cost per QALY of $5211.
- For lecanemab versus SoC, the cost per QALY gained was $2 098 225, whereas donanemab versus lecanemab was $1 460 400.
- The SoC is a cost-effective pharmacological intervention for AD, offering the lowest cost per QALY gains over a 20-year period.
Why it matters
In this cost-effectiveness analysis for Brazil, standard of care was the most cost-effective option, while lecanemab versus standard of care cost $2,098,225 per quality-adjusted life year gained and donanemab versus lecanemab cost $1,460,400. These figures concern cost and value, not whether the drugs cure or prevent Alzheimer disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect size3.5%
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Value in Health Regional Issues) |
| Journal's citation record | 0 / 4 | Value in Health Regional Issues: journal h-index 41 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 7.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Leonardo Régis Leira Pereira: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Glasgow: institution h-index 1,600 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40435868) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.vhri.2025.101130
- PubMed: 40435868
- Original source →
- Free full text: Value in Health Regional Issues →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Price, P. U., Heggie, R., Moriguti, J. C., & Pereira, L. R. L. (2025). Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil. Value in Health Regional Issues. https://doi.org/10.1016/j.vhri.2025.101130
Vancouver
Price PU, Heggie R, Moriguti JC, Pereira LRL. Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil. Value in Health Regional Issues. 2025. doi:10.1016/j.vhri.2025.101130. PMID: 40435868.
BibTeX
@article{price2025-40435868,
author = {Price, Price Udo and Heggie, Robert and Moriguti, Júlio César and Pereira, Leonardo Régis Leira},
title = {{Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil}},
journal = {Value in Health Regional Issues},
year = {2025},
doi = {10.1016/j.vhri.2025.101130},
pmid = {40435868},
url = {https://doi.org/10.1016/j.vhri.2025.101130}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments
Also in Treatments
166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.